Frontiers in Oncology (Jan 2022)

Corrigendum: Anlotinib Combined With Anti-PD-1 Antibodies Therapy in Patients With Advanced Refractory Solid Tumors: A Single-Center, Observational, Prospective Study

  • Min Yuan,
  • Zhongzheng Zhu,
  • Wei Mao,
  • Hui Wang,
  • Hong Qian,
  • Jianguo Wu,
  • Xianling Guo,
  • Qing Xu

DOI
https://doi.org/10.3389/fonc.2021.796625
Journal volume & issue
Vol. 11

Abstract

Read online

No abstracts available.

Keywords